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Sleep disordered breathing: OSA, CSA, 
Pathophysiology and Diagnosis
Obstructive sleep apnea syndrome (OSAS) is a prevalent disorder that has been 
reported to occur in 2 to 4% of middle-aged adults. A similar prevalence of OSAS has 
been reported from India as well. However, this condition is frequently unrecognized 
and underdiagnosed. Important pathophysiological changes in patients with 
obstructive sleep apnea (OSA) is an alteration in human upper airway leading to a 
reduction in cross-sectional area of the upper airway contributing to the easy 
collapsibility of upper airway during sleep. Other pathophysiological changes in OSA 
are oxidative stress, systemic inﬂammation, sympathetic nerve activation, endothelial 
dysfunction, procoagulant activity, intrathoracic pressure changes and metabolic 
dysregulation. The gold standard for diagnosis of OSA is full polysomnography.
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INTRODUCTION
Obstructive sleep apnea is a 
prevalent condition, but frequently 
unrecognized and undiagnosed. The 
important phases of sleep are Non-Rapid 
Eye Movement (NREM) and Rapid Eye 
Movement (REM) sleep. There is 
decrease in sympathetic nervous system 
activity, heart rate, blood pressure, cardiac 
output, systemic vascular resistance and 
metabolic rate in NERM stage, but there is 
an increase in para sympathetic activity 
during NREM stage.  However, there will 
be intermittent surges in sympathetic 
activity during Rapid Eye Movement 
(REM) sleep.
Obstructive sleep apnea :
The  OSA i s  the  repe t i t ive 
interruption of ventilation during sleep 
caused by collapse of the pharyngeal 
airway. OSA is deﬁned as reduction in 
airﬂow associated with upper-airway 
collapse or narrowing that occurs during 
the change from wakefulness to sleep. 
Apnea due to upper airway collapse is 
deﬁned as nearly complete cessation of 
a i r ﬂ o w  a s s o c i a t e d  w i t h  o x y g e n 
desaturation or an arousal from sleep and 
hypopnea is due to partial collapse of 
upper airways. Apnea is deﬁned as 
cessation or near complete cessation that 
is more than 90% reduction of airﬂow > 10 
seconds despite continuing ventilatory 
effort with ﬁve or more such episodes per 
hour of sleep and is usually associated 
with a decrease of > 4% in oxyhemoglobin 
saturation. Hypopnea is characterized by a 
reduction of > 50% in airﬂow for > 10 
seconds associated with a > 3% decrease 
in oxygen saturation and/or arousal (1). 
Central Sleep Apnea (CSA) :
The central sleep apnea (CSA) is 
the repetitive cessation of ventilation 
during sleep resulting from loss of 
ventilatory drive. The manifestations of 
CSA include high altitude induced 
periodic breathing, idiopathic CSA, 
narcotic-induced central apnea, obesity 
hypoventilation syndrome, and Cheyne-
Stokes breathing (2).
Upper Airway Resistance Syndrome : 
There will not be signiﬁcant 
decrease in airﬂow in upper airway 
resistance syndrome, but snoring is usual, 
15 or more episodes of arousal per hour of 
sleep with no signiﬁcant decrease in 
oxyhemoglobin saturation are observed in 
Upper Airway Resistance Syndrome. 
Pickwickian Syndrome - Obesity 
Hypoventilation Syndrome : 
This entity consists of obesity, 
sleep disordered breathing, hypoxia and 
chronic hypercapnea during wakefulness 
in the absence of other known causes of 
hypercapnea. This was described as 
“Pickwickian Syndrome” in 1956 in a 
case report as the patient reported in this 
report resembled a character depicted by 
Dickens in his book “The posthumous 
papers of the Pickwick club” because both 
were obese with excessive hyper 
somnolence (3).  
Apnea-Hypopnea Index :
Apnea-Hypopnea Index (AHI) is 
the number of apneas and hypopneas per 
hour of sleep conﬁrmed by electro-
encephalogram (EEG).  Apnea-hypopnea 
index (AHI) is used to characterize OSA. 
Another index that is used is Respiratory 
Disturbance Index (RDI) and this is the 
number of apneas, hypopneas and 
respiratory effort related arousals per hour 
of sleep conﬁrmed by EEG. The severity 
of OSA is classiﬁed based on apnea 
hypopnea index. AHI more than 5 and less 
than 15 events/hour of sleep is mild OSA, 
AHI between 15 to 30 events/ hour of 
sleep is moderate OSA and  AHI more 
than 30 events/ hour of sleep is severe 
OSA.  OSAS is deﬁned as sleep 
disordered breathing associated with 
daytime symptoms most often excessive 
daytime sleepiness. It has been estimated 
that the OSAS affects 2 to 4% of middle-
aged adults (4). 
Risk factors :
Risk factors for development of 
OSA are classiﬁed as non-modiﬁable and 
modiﬁable factors (2, 3).  The non-
modiﬁable risk factors are age, gender 
(male), ethnicity (being black, Hispanic), 
anatomical abnormalities of craniofacial 
regions and upper airway, thick neck with 
circumference more than 17 inches in 
males and more than 16 inches in females 
and a genetic predisposition (5).  The 
modiﬁable risk factors are excessive body 
weight (obesity), use of alcohol, sedatives 
or tranquilizers, narrowed airways due to 
enlarged tonsils or adenoids, smoking, 
chronic nasal congestion, hypertension, 
diabetes melli tus,  myxedema and 
menopause (6). Wisconsin sleep study had 
identiﬁed baseline obesity, older age and 
presence of snoring as factors important in 
progression of disease (4). 
Upper airway anatomy : 
The human upper airway is 
composed of numerous muscles and soft 
tissue but it lacks bony support.  It has 
been observed that the cross sectional area 
of the upper airway during wakefulness is 
reduced in patients with OSA compared 
with subjects without OSA, thereby 
leading to collapse of the upper airway 
during sleep (7). 
Pathophysiology  :
  OSA-induced biological changes 
include intermittent hypoxia, intermittent 
hypercapnia, intra thoracic pressure 
changes, sympathetic activation and sleep 
fragmentation (8). Chronic intermittent 
hypoxia is the cardinal feature of OSA. 
During intermittent hypoxia, there will be 
repeated episodes of hypoxia and 
normoxia resembling ischemia/perfusion 
events (9).  During hypoxic/ischemic 
phase, the cells adapt to low O2 
environment and during reoxygenation/ 
reperfusion phase, there will be sudden 
increase of oxygen in the cells resulting in 
the production of reactive oxygen species 
(ROS) (9, 10).
  OSA can cause sympathetic 
activation, metabolic dysregulation, 
endothelial dysfunction, systemic 
inﬂammation, oxidative stress, and hyper 
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coagulation and neurohumoral changes. 
These changes may lead to hypertension 
(both systemic and pulmonary), heart 
fa i lure ,  a r rhythmias ,  myocardia l 
infarction, stroke and sudden cardiac 
death.  Repetitive episodes of upper 
airway narrowing and / or occlusion cause 
hypoxemia, reoxygenation, swings in 
intra thoracic pressure and central nervous 
system arousals.  These factors can cause 
acute stress on cardiovascular system and 
the cumulative effects from these can lead 
t o  d i s r u p t i o n  o f  c a r d i o v a s c u l a r 
homeostatic mechanisms.  These may 
lead to daytime abnormali t ies in 
sympathetic nervous system function and 
to heart rate variability (11).
a) Oxidative stress :
   Many studies have reported a role 
of oxidative stress in patients with OSA 
(12). Studies had demonstrated that there 
was an increase in thiobarbituric acid-
reactive substances (TBARS) levels in 
patients with severe OSA compared with 
healthy control subjects and treatment 
with continuous positive airway pressure 
(CPAP) reduced the lipid peroxidation 
events (13-15). It was also reported that 
there was an increased level of oxidized 
low-density lipoprotein levels in OSA.  
Inhibition of xanthine oxidase by 
allopurinol and supplemental intake of 
vitamin C have been shown to improve 
endothelial function in patients with OSA. 
Glycation products, the end result of 
oxidative stress were also reported to be 
increased in OSA patients with normal 
glucose homeostasis.  The demonstration 
tha t  u r ina ry  8  -  hydroxy  -  29  -
d e o x y g u a n o s i n e  e x c r e t i o n  w a s 
signiﬁcantly higher in patients with severe 
OSA versus control subjects suggests 
oxidative DNA damage in OSA. The 
antioxidant capacity in the blood which 
acts as defense against free radicals has 
also been found to be reduced in OSA 
compared to control  subjects .  In 
observational studies, a derangement in 
the oxidant-anti-oxidant balance with a 
shift towards oxidative stress was 
documented and treatment with the anti-
oxidants (vitamin E, vitamin C and N-
acetyl cysteine) had demonstrated a 
reduction in oxidative stress in OSA 
patients (15, 16).  The results from these 
studies indicate the occurrence of 
oxidative stress in patients with OSA. 
However, there are studies that have not 
demonstrated increased oxidative stress in 
OSA (17). 
b) Systemic inﬂammation :
  It has been noticed that CD4 and 
CD8 T cells of patients with OSA undergo 
phenotypic and functional changes with a 
shift towards type 2 cytokines dominance 
and increased IL4 production (18). A 
marked increase in TNF-α and CD40 
ligand in CD8 T cells from patients with 
OSA was also reported. CPAP treatment 
i m p r o v e d  o r  r e v e r s e d  a l l  t h e s e 
abnormalities in OSA patients (18, 19).  
Increased circulating levels of CRP have 
been consistently reported in both adults 
(20, 21), as well as in children with OSA 
(22) and are reduced on effective 
treatment (20, 23). It has been reported 
that there is an independent association 
between severity of OSA and elevated 
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CRP level in men without comorbidities 
(24).  Nuclear factor kappa B (NF-kB), an 
important factor for activation of 
inﬂammatory pathways, has been found to 
be increased in OSA (25). Expression of 
adhesion molecules on circulating 
monocytes may indicate activation of 
systemic inﬂammation in OSA (26).  It 
has been reported that TNF-α -308 
polymorphism is associated with OSA 
(27).
c) Sympathetic Nerve Activation :
An increased sympathetic nerve 
activity has been reported in OSA (28). 
The increase in sympathetic activity 
during sleep may be due to the activation 
of peripheral chemoreceptors by hypoxia, 
hyper-capnea and apneas leading to 
peripheral vasoconstriction and increase 
in blood pressure (29). It has also been 
demonstrated that there is exaggerated 
sympathetic activity during daytime 
w a k e f u l n e s s  d e s p i t e  n o r m o x i a            
(30).  Increased concentrations of 
catecholamines in urine and elevated 
levels of norepinephrine in plasma were 
also seen in patients with OSA (31). 
Muscle sympathetic nerve activity 
(MSNA) has been found to be elevated in 
OSA during wakefulness (28) and CPAP 
therapy reduces the high sympathetic 
activity. An increase in resting heart rate 
during wakefulness has been observed in 
OSA patients suggesting that there is an 
increase in cardiac sympathetic drive in 
OSA (32). Thus chronic sympathetic 
activation may be an important factor for 
the development of cardiovascular 
disease in OSA (33).
d) Endothelial dysfunction :
Endothelial dysfunction in OSA is a 
risk factor for cardiac abnormalities        
in OSA (34). Endothelial dysfunction      
i n  O S A m a y  b e  d u e  t o  c h r o n i c  
intermittent hypoxia and to sleep loss   
and fragmentation. The endothelial 
dysfunct ion  resu l t s  in  increased 
v a s o c o n s t r i c t i o n  a n d  r e d u c e d 
vasodilation. Nitric oxide which is a 
powerful vasodilator is decreased in OSA 
and the decreased levels of nitric oxide 
may contribute to reduced vasodilation 
and platelet adhesion and aggregation. 
Treatment of OSA has been found to 
increase nitric oxide levels in OSA (35). 
Recurrent hypoxemia has been found to 
increase the endothelin levels in OSA and 
there is a reduction in endothelin levels on 
treatment with CPAP (36). Endothelin is a 
potent vasoconstrictor which causes 
elevated blood pressure. Endothelial 
dysfunction is one of the important factors 
that are responsible for cardiovascular 
diseases in OSA.  
e) Procoagulant activity :
Several studies in OSA patients 
had shown that there are elevated levels of 
plasma ﬁbrinogen, exaggerated platelet 
activity and reduced ﬁbrinolytic activity 
suggesting that there is a hypercoagulable 
state in OSA (37). The exaggerated 
platelet activity has been found to be 
reduced following treatment with CPAP 
(38). There is also an increase in mean 
platelet volume which has been reduced 
by CPAP therapy in OSA patients. 
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f) Intrathoracic pressure changes :
During obstructive sleep apnea, 
the repetitive inspiratory efforts against a 
closed upper airway lead to increased 
negative intrathoracic pressure. As a 
result, there will be an increase in 
transmural gradients across the atria, 
ventricles and aorta. This is similar to the 
Muóller maneuver in which an individual 
inspires against closed glottis leading to a 
pleural pressure of -30 cm H O (39). 
2
These changes in transmural gradients can 
result in autonomic and hemodynamic 
instability (30, 40). An increase in aortic 
transmural pressure can cause aortic 
dissection in OSA patients. 
g) Metabolic dysregulation :
There are evidences suggesting that 
OSA is independently associated with 
metabolic syndrome (41). Chronic 
i n t e r m i t t e n t  h y p o x i a  a n d  s l e e p 
deprivation with sleep loss may play a role 
to trigger inﬂammation leading to 
metabolic syndrome.  OSA may be a risk 
factor for metabolic syndrome. Obesity 
particularly central adiposity is a potent 
risk factor for sleep apnoea (42). An 
interaction of obesity-OSA-metabolic 
syndrome involving many mechanisms 
has been postulated (43). The National 
Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III) report 
recommends the use of ﬁve variables 
(hypertension, insulin resistance or 
glucose intolerance, low serum high-
density lipoprotein (HDL) cholesterol, 
e levated serum tr iglycer ide ,  and 
abdominal obesity) with set threshold 
values for each variable for clinical 
characterization of metabolic syndrome. 
Subjects meeting three of these ﬁve 
criteria are classiﬁed as having metabolic 
syndrome. The cut off value for deﬁning 
abdominal obesity may vary based on 
ethnicity (44). Features associated      
with metabolic syndrome are pro 
inﬂammatory state, prothrombotic state, 
hyperleptinemia, hypo-adiponectinemia, 
hyperuricemia, endothelial dysfunction 
and microalbuminuria (45).  
Diagnosis : 
Diagnosis of OSA is based on 
s y m p t o m  a s s e s s m e n t ,  c l i n i c a l 
examination and laboratory investigations 
mainly by polysomnography.
a) Symptom assessment : 
Symptoms can occur during sleep 
and during wakefulness. The most 
common symptoms during sleep are 
snoring, snorting, choking attacks 
terminating a snore and witnessed apneas 
by bed partner. Other nocturnal symptoms 
inc lude  non  -  r e s to ra t ive  s l eep ,     
nocturnal restlessness, vivid dreams, 
gastroesophageal reﬂux, insomnia with 
frequent awakenings, nocturia, hyper 
salivation and diaphoresis. Symptoms 
reported during awake are excessive 
daytime sleepiness, lack of concentration, 
cognitive deﬁcits,  mood changes, 
morn ing  headaches ,  d ry  mou th , 
impotence and decreased libido. The 
severity of excessive daytime sleepiness 
can  be  subjec t ive ly  assessed  by 
questionnaires; the most commonly used 
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questionnaire is Epworth Sleepiness 
Scale. Objective tests that can assess 
excessive daytime sleepiness include 
Multiple Sleep Latency Test (MSLT) and 
the Maintenance of Wakefulness Test 
(MWT) and the Osler Test, but these tests 
are costly and time consuming (46). The 
interview of the partner is also important 
while assessing the patients with 
suspected OSA.  
b) Clinical features :
The clinical features associated 
with OSA are obesity (particularly central, 
2
body mass index more than 30 kg/m ), 
large neck circumference (more than 40 
cm), narrow mandible, narrow maxilla, 
retrognathia, dental malocclusion, 
overbite, reduced nasal patency, high and 
narrow hard palate, elongated and low-
lying uvula, enlarged tonsils, enlarged 
adenoids and macroglossia. Clinical 
examination of a patient suspected          
to be suffering from OSA includes 
measurement  o f  b lood  pressure , 
c a r d i o r e s p i r a t o r y  a u s c u l t a t i o n , 
examination of the oral cavity and noting 
the presence of teeth and dentures. The 
assessment of the tonsils, tongue size, 
architecture of hard palate and faucal 
pillars are important. Mallampati score 
can be used to assess the upper airway in 
OSA. 
c) Laboratory diagnosis :
The “Gold standard” for the 
d i a g n o s i s  o f  O S A  i s  f u l l 
polysomnography and it provides detailed 
information on sleep state and respiratory 
and gas exchange abnormalities (47). 
Other  var iab les  assessed  dur ing 
polysomnography are body position, heart 
rate and rhythm, and muscle tone and 
contract ion.  Polysomnography is 
resource intensive requiring a full sleep 
laboratory and a trained technician. A  
minimum of 12 channels of recordings 
that include electroencephalogram 
(EEG),  electrooculogram (EOG), 
electromyogram (EMG), oronasal 
airﬂow, chest wall effort, body position, 
snore microphone, electrocardiogram 
(ECG), and oxyhemoglobin saturation are 
usually used in polysomnographic (PSG) 
studies. The duration of the diagnostic 
study should be at least 6 hours. 
However,  when there is an 
obvious case of OSA, split-night studies, 
in which the ﬁrst half of the study night is 
used for diagnosis and the second half to 
monitor treatment response using CPAP 
are also used. Because of the cost factor 
and the requirement of a trained 
technician, home-based sleep studies 
involving limited cardiorespiratory 
assessments are also advocated as an 
alternative to hospital based detailed 
polysomnographic studies. Cardio-
respiratory monitoring which involves the 
measurement of airﬂow, respiratory 
effort, oxygen saturation and heart rate, 
but not EEG has been used to assess sleep 
apnea. Overnight oximetry is also used as 
a screening test to evaluate suspected 
cases of OSA by continuous recording of 
oxygen saturation (SaO2) during sleep. 
The characteristic pattern of desaturation 
in OSA is repetitive desaturation and 
oximetry may therefore be useful in 
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